NCT03542162 is a NA clinical trial of Healaflow in Rhegmatogenous Retinal Detachment, sponsored by Tianjin Medical University Eye Hospital.

Who is sponsoring NCT03542162?

NCT03542162 is sponsored by Tianjin Medical University Eye Hospital.

What drugs are being tested in NCT03542162?

Interventions in NCT03542162: Healaflow.

What condition does NCT03542162 study?

NCT03542162 studies Rhegmatogenous Retinal Detachment.

Is NCT03542162 still recruiting?

NCT03542162 is currently completed. Last updated 30 April 2019.

Last reviewed 2019-04-30 · How we verify

NCT03542162

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment

Completed NA Last updated 30 April 2019

What this trial tests

NA trial testing Healaflow in Rhegmatogenous Retinal Detachment in 37 participants. Completed in 1 December 2018.

Timeline

1 January 2017

Primary endpoint
1 July 2018

1 December 2018

Quick facts

Lead sponsor	Tianjin Medical University Eye Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	1 January 2017
Primary completion	1 July 2018
Estimated completion	1 December 2018

Drugs / interventions tested

Healaflow — full drug profile →

Conditions studied

Rhegmatogenous Retinal Detachment — all drugs for Rhegmatogenous Retinal Detachment →

Sponsor

Tianjin Medical University Eye Hospital

Who can join

Eligibility, any sex, with Rhegmatogenous Retinal Detachment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To report the surgical results of primary rhegmatogenous retinal detachment (RRD) repaired by 27G pars plana vitrectomy (PPV) combined with Healaflow patch and air tamponade, and do not need prone position postoperation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

PATCHING RETINAL BREAKS WITH HEALAFLOW IN 27-GAUGE VITRECTOMY FOR THE TREATMENT OF RHEGMATOGENOUS RETINAL DETACHMENT.
Ren XJ, Bu SC, Wu D, Liu BS, et al · · 2020 · cited 10× · PMID 31860522 · DOI 10.1097/iae.0000000000002701
Frontier applications of retinal nanomedicine: progress, challenges and perspectives.
Tang Z, Ye F, Ni N, Fan X, et al · · 2025 · cited 6× · PMID 40001147 · DOI 10.1186/s12951-025-03095-6

Verify or expand the search:

Other recruiting trials for Rhegmatogenous Retinal Detachment

Currently open trials in the same condition.

NCT07283614 — Ocular Hypotony and Refractive Predictability in RRD Surgery · NA · active not recruiting
NCT07081945 — hAM for Inferior RRD · NA · recruiting
NCT06997874 — Treatment of Retinal Detachment in People Who Have Not Had Cataract Surgery With Vitrectomy vs Vitrectomy and Cataract R · Phase 3 · recruiting
NCT06826573 — Analysis of Risk Factors for High Intraocular Pressure and Retinal Detachment Recurrence After Vitrectomy with Silicone · recruiting
NCT05660447 — A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR · Phase 2, PHASE3 · active not recruiting

Other Tianjin Medical University Eye Hospital trials

Trials by the same sponsor.

NCT07494799 — Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear · not yet recruiting
NCT07449247 — PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention · Phase 1, PHASE2 · not yet recruiting
NCT05728476 — Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Dia · NA · recruiting
NCT05990829 — Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed · Phase 4 · unknown
NCT07106268 — Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03542162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Eye Hospital
Last refreshed: 30 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03542162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing